INTERPACE BIOSCIENCES Files 8-K on Financials
Ticker: IDXG · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1054102
| Field | Detail |
|---|---|
| Company | Interpace Biosciences, Inc. (IDXG) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, company-history
TL;DR
INTERPACE BIOSCIENCES dropped an 8-K on March 7th covering financials and operations.
AI Summary
On March 7, 2024, INTERPACE BIOSCIENCES, INC. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the earliest event reported as of March 7, 2024. The company, formerly known as Interpace Diagnostics Group, Inc., is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus industry.
Why It Matters
This 8-K filing provides crucial updates on INTERPACE BIOSCIENCES, INC.'s financial performance and operational status, which is essential for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not indicate any unusual or significant negative events.
Key Players & Entities
- INTERPACE BIOSCIENCES, INC. (company) — Registrant
- March 7, 2024 (date) — Date of earliest event reported
- Interpace Diagnostics Group, Inc. (company) — Former company name
- PDI INC (company) — Former company name
- PROFESSIONAL DETAILING INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for INTERPACE BIOSCIENCES, INC.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
What was the earliest event date reported in this filing?
The earliest event reported was as of March 7, 2024.
What are some of the former names of INTERPACE BIOSCIENCES, INC.?
The company was formerly known as Interpace Diagnostics Group, Inc., PDI INC, and PROFESSIONAL DETAILING INC.
In which state is INTERPACE BIOSCIENCES, INC. incorporated?
The company is incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for INTERPACE BIOSCIENCES, INC.?
The SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-03-12 19:42:48
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 97KB
- 0001493152-24-009737.txt ( ) — 315KB
- idxg-20240307.xsd (EX-101.SCH) — 3KB
- idxg-20240307_lab.xml (EX-101.LAB) — 34KB
- idxg-20240307_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Waterview Plaza , Suite 310 2001 Route 46 , Parsippany , NJ 07054 (Address, including zip code, of Principal Executive Offices) (855) 776-6419 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On March 7, 2024, Interpace Biosciences, Inc. issued a press release announcing its preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release, dated March 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interpace Biosciences, Inc. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: March 12, 2024